The combination of YM155 and chemotherapeutic drugs (including etoposide, platinum, doxetaxel) enhanced inhibition of survivin expression, resulting in stronger inhibition of tumor growth in some cancer types such as non-small cell lung cancer, melanoma and neuroblastoma. This evidence concerns the gene BIRC5 and melanoma.